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PRELIMINARY AND SHORT REPORTS
THE EFFECT OF TOPICALLY APPLIED COMPOUND F IN SELECTED
DERMATOSES
MARION B. SIJLZBERGER, M.D. AND VICTOR H. WITTEN, M.D.
It has been the experience of most investigators, with a few exceptions, that the topical
use of cortisone acetate ointment is without value in the treatment of diseases of the skin.
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2. (H. W.)
3. (M. S.)
4. (H. S.)
5. (C. W.)
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11. (W. S.)
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15. (W. H.)
Atopic dermatitis
Atopic dermatitis
Atopic dermatitis
Atopie dermatitis
Atopic dermatitis
Atopic dermatitis
Atopic dermatitis (?)
Atopic dermatitis (?)
Psoriasis
Psoriasis
Chronic discoid lupus ery-
thematosus
Chronic discoid lupus cry-
thematosus
Chronic discoid lupus cry-
thematosus
Chronic discoid lupus ery-
thematosus
Widespread discoid or sub-
acute lupus erythematosus
Exudative discoid and lichen-
oid chronic dermatosis
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Alopecia areata
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x
x
x
x
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No improvement (?)
No control
No improvement
No control
No improvement
x
No control
No improvement
No control
No improvement
No control
No improvement
When compound F (17-hydroxycorticosterone-21-acetate) was made available to us, we
had an ointment prepared containing the crystalline material in a concentration of 25 mg.
Comparison Between Areas Treated with Compound F Ointment and Those Treated with
Control Ointment
COMPOUND P TREATED AREAS AS COMPARED
TO CONTROL SITE
CASE ACE SEX DIAGNOSIS
Much
better Slightlybetter No better
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x
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x
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F
F
F
F
34 M
41 M
20 F
46
16. (A. K.)
17. (E. S.)
18. (C. L.)
19. (W. K.)
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* We are indebted to the medical division of Merck & Co., Inc., Rahway, New Jersey
for supplying the crystalline hydrocortisone acetate.
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per gram of base. The base was composed of:
lanolin 15%
liquid petrolatum 10%
white petrolatum qs
For this study we selected patients from private practice generally presenting dermatoses
of long standing. In all cases, we have had an opportunity to observe a general refractoriness
to various forms of topical therapy, including in many instances topical applications of
cortisone acetate. An attempt was made to choose patients who had involvement of sym-
metrical sites so that the compound F ointment could be used on one area and the ointment
base alone on the contralateral site. The subjects were instructed to rub very small ap-
proximately equal quantities of the compound F ointment and the ointment base into the
respective involved sites two to three times daily. We were able to observe our patients at
weekly intervals.
In those cases in which improvement occurred with the use of the compound F ointment,
it was noted at the first observation period after one week's use. This improvement was
maintained for as long as the compound F was used, the longest time being four weeks.
Improvement was judged by decreased pruritus, diminished erythema, reduced scaling and
beginning clearing of the dermatosis under treatment.
It is of interest to note that in six of the eight cases of proved or presumptive atopic
dermatitis, the compound F ointment produced greater improvement than did the base
alone. However, in six of these cases there was some improvement also from the ointment
base alone without compound F. In case 15 (W. H.) with widespread discoid or subacute
lupus erythematosus, there was some improvement at the control site but likewise less
than at the compound F treated area.
In case 3 (M. S.) there was not only improvement of the immediately treated areas but
also of the areas distant from the actual sites of application. This clinical observation of
therapeutic effectiveness beyond and removed from the site of application of the compound
F ointment may perhaps be related to the findings of Goldman, Preston and Rockwell (1)
who demonstrated a zone of inhibition to patch test reactions which extended beyond the
immediate area of intradermal injection of compound F solution. In our patient M. S., on
stopping use of compound F ointment and continuing with only the ointment base without
compound F, the dermatosis recurred in all sites. When compound F-containing ointment
was again applied, improvement was again noted within a few days.
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